Coherus Offers Positive Phase III Data on Humira Biosimilar

Coherus BioSciences Inc CHRS reported encouraging top line data from an ongoing part 3 of a phase III study on its biosimilar version of AbbVie Inc s ABBV Humira adalimumab CHS 1420 for the treatment of patients with psoriasis Coherus share price has surged 91 9 in the past one